EPFL Investor Day 2024

10 Dec 2024 | Lausanne, Switzerland

Moustafa Houmani

Cofounder & CEO

Lemna Bio

Lausanne, Switzerland

30 profile visitsSpeaker

A biochemical engineer by training and a second-time biotech founder. On a mission for driving bio-innovation to create transformative value.

My organisation

Lemna Bio

Lemna Bio

Startup in Creation

Lausanne, Switzerland

Team Moustafa Houmani: Cofounder & CEO. EPFL Biochemical Engineer. Second-time biotech founder., Lucien Krapp: Cofounder & CSO. EPFL Physics PhD. Invented Lemna's Core Technology. Rising star in the field., Matteo Dal Peraro: Scientific Cofounder. Head of the Laboratory of Biomolecular Modeling (LBM) at EPFL. Lemna Bio: Vision, Technology, and Impact Rising costs and frequent failures are stifling innovation in pharma. Lemna Bio is transforming the landscape with its geometric transformer technology for atomistic, dynamic, and context-specific biomolecule modeling. Our validated models—PeSTo for interaction prediction and Carbonara for protein sequence design—have garnered strong interest from leading pharmaceutical and biotech companies, including Novo Nordisk, Novartis, Lonza, BMS, Moderna, and Syngenta. Carbonara, benchmarked by Novo Nordisk, was recognized as one of the top two best-in-class models. Incorporating insights and feedback from our pharma conversations, we are now developing a flagship diffusion model to enable structure generation with integrated context across scales. Building Partnerships While we are not actively raising funds at this time, we are keen to connect with like-minded investors who recognize the transformative potential of AI in biomolecule design. We seek to build strong relationships with those who understand the profound impact Lemna's technology can have on reshaping the future of therapeutics and beyond.
Read more

About me

My organisation

Lemna Bio

Team

  • Moustafa Houmani: Cofounder & CEO. EPFL Biochemical Engineer. Second-time biotech founder.

  • Lucien Krapp: Cofounder & CSO. EPFL Physics PhD. Invented Lemna's Core Technology. Rising star in the field.

  • Matteo Dal Peraro: Scientific Cofounder. Head of the Laboratory of Biomolecular Modeling (LBM) at EPFL.

Lemna Bio: Vision, Technology, and Impact

Rising costs and frequent failures are stifling innovation in pharma. Lemna Bio is transforming the landscape with its geometric transformer technology for atomistic, dynamic, and context-specific biomolecule modeling.

Our validated models—PeSTo for interaction prediction and Carbonara for protein sequence design—have garnered strong interest from leading pharmaceutical and biotech companies, including Novo Nordisk, Novartis, Lonza, BMS, Moderna, and Syngenta. Carbonara, benchmarked by Novo Nordisk, was recognized as one of the top two best-in-class models.

Incorporating insights and feedback from our pharma conversations, we are now developing a flagship diffusion model to enable structure generation with integrated context across scales.

Building Partnerships

While we are not actively raising funds at this time, we are keen to connect with like-minded investors who recognize the transformative potential of AI in biomolecule design. We week to build strong relationships with those who understand the profound impact Lemna's technology can have on reshaping the future of therapeutics and beyond.

Speaker sessions (1)

Tuesday, 10 December 2024

17:30 - 18:00

Pitch Session Startups in creation

Format:In-personLocation:Pitch Area 1Track:Pitch Session

The final pitch session will spotlight startups in the creation phase, offering a sneak peek at the next wave of market-disrupting innovations.